{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:08:50Z","timestamp":1778962130062,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.remnie.2023.02.009","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T14:34:14Z","timestamp":1678026854000},"page":"203-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["18F-DCFPyL PET\/CT guidelines"],"prefix":"10.1016","volume":"42","author":[{"given":"A.L.","family":"Guti\u00e9rrez Cardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Vallejo Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Garc\u00eda Garz\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Tirado Hospital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Medina L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Freire Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rodr\u00edguez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2023.02.009_bib0005","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2023.02.009_bib0010","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2019.37.15_suppl.5012","article-title":"Diagnostic performance of F-18-DCFPyL in the OSPREY Trial: a prospective phase 2\/3 multicenter study of F-18-DCFPyL PET\/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC)","volume":"37","author":"Morris","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.remnie.2023.02.009_bib0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.02.009_bib0020","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s00259-017-3725-1","article-title":"Development of standardized image interpretation for 68Ga-PSMA PET\/CT to detect prostate cancer recurrent lesions","volume":"44","author":"Fanti","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2023.02.009_bib0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","article-title":"PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies","volume":"73","author":"Rowe","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.remnie.2023.02.009_bib0030","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2967\/jnumed.121.262989","article-title":"18F-DCFPyL PET acquisition, interpretation, and reporting: suggestions after food and drug administration approval","volume":"63","author":"Song","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.02.009_bib0035","series-title":"Las cifras del cancer en Espa\u00f1a ISBN: 978-84-09-38029-9 \u00a9","year":"2022"},{"key":"10.1016\/j.remnie.2023.02.009_bib0040","unstructured":"Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214793s000lbl.pdf."},{"key":"10.1016\/j.remnie.2023.02.009_bib0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pcan.2015.25","article-title":"Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer","volume":"18","author":"Moreira","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.remnie.2023.02.009_bib0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.remnie.2023.02.009_bib0055","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2967\/jnumed.117.207316","article-title":"Effects of fasting on 18F-DCFPyL uptake in prostate cancer lesions and tissues with known high physiologic uptake","volume":"59","author":"Wondergem","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.02.009_bib0060","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2967\/jnumed.117.192658","article-title":"18F-DCFPyL PET\/CT in the detection of prostate cancer at 60 and 120 minutes: detection rate, image quality, activity kinetics, and biodistribution","volume":"58","author":"Wondergem","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.02.009_bib0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/MNM.0000000000001007","article-title":"Effect of forced diuresis during 18F-DCFPyL PET\/CT in patients with prostate cancer: activity in ureters, kidneys and bladder and occurrence of halo artefacts around kidneys and bladder","volume":"40","author":"Wondergem","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.remnie.2023.02.009_bib0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13550-022-00913-y","article-title":"Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET\/CT: a single-centre retrospective study","volume":"12","author":"Donswijk","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.remnie.2023.02.009_bib0075","unstructured":"Available from: https:\/\/seom.org\/images\/NdP_Avances_Cancer_de_Prostata_2021.pdf."},{"key":"10.1016\/j.remnie.2023.02.009_bib0080","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00259-022-05721-z","article-title":"Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET\/CT and uptake characteristics in 1445 patients","volume":"49","author":"Perry","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2023.02.009_bib0085","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer","volume":"17","author":"Chen","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.remnie.2023.02.009_bib0090","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11307-021-01670-5","article-title":"A pilot study of dynamic 18F-DCFPyL PET\/CT imaging of prostate adenocarcinoma in high-risk primary prostate cancer patients","volume":"24","author":"Lu","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.remnie.2023.02.009_bib0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol Imaging Biol"},{"issue":"Suppl 2","key":"10.1016\/j.remnie.2023.02.009_bib0100","first-page":"519","article-title":"Normal organ uptake variability on PSMA-targeted 18F-DCFPyL PET\/CT","volume":"57","author":"Li","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.02.009_bib0105","doi-asserted-by":"crossref","first-page":"55094","DOI":"10.18632\/oncotarget.19049","article-title":"Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer","volume":"8","author":"Gaertner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.remnie.2023.02.009_bib0110","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","article-title":"A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies","volume":"59","author":"O\u2019Keefe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.02.009_bib0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.remnie.2023.02.009_bib0120","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.oooo.2018.01.011","article-title":"Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET\/CT","volume":"125","author":"Klein Nulent","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.remnie.2023.02.009_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40644-020-00300-7","article-title":"Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings","volume":"20","author":"de Galiza Barbosa","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.remnie.2023.02.009_bib0130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.02.009_bib0135","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.02.009_bib0140","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2023.02.009_bib0145","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0","volume":"59","author":"Rowe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.02.009_bib0150","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3390\/jcm8071060","article-title":"Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for theranostic radiotracers-navigating pitfalls of SSTR- and PSMA-targeted PET\/CT","volume":"8","author":"Werner","year":"2019","journal-title":"J Clin Med"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808923000265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808923000265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:47:07Z","timestamp":1778960827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808923000265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2253808923000265"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2023.02.009","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18F-DCFPyL PET\/CT guidelines","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2023.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2023.01.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}